Combination of Niraparib and Lapatinib for Ovarian Cancer Treatment
Cancer Research and Treatment · 15.07.2026 · 58 (3) · 906-922
DOI: 10.4143/crt.2025.553 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, erschienen am 15.07.2026. Verfasst von Feiyun Jiang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, East China Normal University Wuhu Affiliated Hospital (The Second People's Hospital of Wuhu City), Wuhu, China. Hauptthemen laut MEDLINE: Piperidines, Ovarian Neoplasms, Lapatinib, Indazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Health Research Program of Anhui Province.
Abstract (Originalsprache)
Purpose
Ovarian cancer is characterized by high malignancy, frequent recurrence with drug resistance, and poor 5-year survival rates. Although poly(ADP-ribose) polymerase (PARP) inhibitors like niraparib show efficacy in homologous recombination repair-deficient ovarian cancer, resistance often develops. This study aimed to evaluate the synergistic therapeutic potential of combining the epidermal growth factor receptor (EGFR) inhibitor lapatinib and the PARP inhibitor niraparib to evaluate combinatorial effects and enhance antitumor effects in ovarian cancer.Materials and Methods Lapatinib (EGFR inhibitor) and niraparib (PARP inhibitor) were screened from the U.S. Food and Drug Administration/China Food and Drug Administration–approved drug library. In vitro assays assessed ovarian cancer cell proliferation, clonogenicity, metastatic ability, and apoptosis. Mechanistic studies analyzed phosphorylation levels of EGFR, AKT, and ERK via biochemical assays. In vivo experiments were conducted to validate the antitumor efficacy of the drug combination.
Results
The lapatinib-niraparib combination synergistically suppressed ovarian cancer cell proliferation, inhibited clonogenic formation and metastasis, and induced apoptosis. Mechanistically, the dual therapy reduced phosphorylation of EGFR, AKT, and ERK, indicating suppression of downstream signaling pathways. Both in vitro and in vivo experiments demonstrated significant inhibition of ovarian cancer growth with the combination treatment.
Conclusion
EGFR/human epidermal growth factor receptor 2–expressing ovarian cancer cells responded to lapatinib and that a synergistic effect was observed when combined with niraparib. These findings highlight its promising clinical potential for improving outcomes in ovarian cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology, East China Normal University Wuhu Affiliated Hospital (The Second People's Hospital of Wuhu City), Wuhu, China.
- Department of Obstetrics, East China Normal University Wuhu Affiliated Hospital (The Second People's Hospital of Wuhu City), Wuhu, China. 1767361775@qq.com.
- Department of Gynecology, East China Normal University Wuhu Affiliated Hospital (The Second People's Hospital of Wuhu City), Wuhu, China. tb189494@163.com.
Förderung
- Health Research Program of Anhui Province
Zitieren
APA
Jiang, F., Liu, X., Wei, Y., Ding, Y., Cai, W., Xu, S., & Tang, B. (2026). Combination of Niraparib and Lapatinib for Ovarian Cancer Treatment. Cancer Research and Treatment, 58(3), 906-922. https://doi.org/10.4143/crt.2025.553
Vancouver
Jiang F, Liu X, Wei Y, Ding Y, Cai W, Xu S, et al. Combination of Niraparib and Lapatinib for Ovarian Cancer Treatment. Cancer Research and Treatment. 2026;58(3):906-922. doi:10.4143/crt.2025.553
BibTeX
@article{Jiang2026,
author = {Jiang, Feiyun and Liu, Xingyu and Wei, Yalan and Ding, Yeping and Cai, Wen and Xu, Shanshan and Tang, Bin},
title = {Combination of Niraparib and Lapatinib for Ovarian Cancer Treatment},
journal = {Cancer Research and Treatment},
year = {2026},
volume = {58},
number = {3},
pages = {906--922},
doi = {10.4143/crt.2025.553}
}
EUVIMED